ELI LILLY AND COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 732.2 USD | -1.81% |
|
-2.47% | +25.61% |
| Apr. 23 | Global markets live: Bayer, PepsiCo, Halliburton, Spotify, Apple... |  |
| Apr. 23 | Alzheimer's drug adoption in US slowed by doctors' skepticism | RE |
Financials (USD)
| Sales 2024 * | 41.36B | Sales 2025 * | 51.29B | Capitalization | 672B |
|---|---|---|---|---|---|
| Net income 2024 * | 10.88B | Net income 2025 * | 15.79B | EV / Sales 2024 * | 16.6 x |
| Net Debt 2024 * | 15.19B | Net Debt 2025 * | 10.74B | EV / Sales 2025 * | 13.3 x |
| P/E ratio 2024 * |
61.4
x | P/E ratio 2025 * |
41.6
x | Employees | 43,000 |
| Yield 2024 * |
0.69% | Yield 2025 * |
0.8% | Free-Float | 99.79% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eli Lilly and Company
More recommendations
More press releases
More news
| 1 day | -1.81% | ||
| 1 week | -1.95% | ||
| Current month | -5.88% | ||
| 1 month | -4.98% | ||
| 3 months | +16.28% | ||
| 6 months | +26.97% | ||
| Current year | +25.61% |
1 week
722.07
752.64
1 month
722.07793.67
Current year
579.05800.78
1 year
370.68800.78
3 years
178.58800.78
5 years
101.36800.78
10 years
57.81800.78
| Managers | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 95-12-31 |
Anat Ashkenazi
DFI | Director of Finance/CFO | 51 | 00-12-31 |
Ruth Gimeno
PSD | President | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 21-01-24 | |
Ralph Alvarez
BRD | Director/Board Member | 67 | 09-03-31 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 04-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 6.49% | 18 M€ | +4.24% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 732.2 | -1.81% | 2,131,604 |
| 24-04-23 | 745.7 | +1.96% | 2,042,029 |
| 24-04-22 | 731.3 | +0.69% | 2,354,096 |
| 24-04-19 | 726.3 | -2.63% | 3,505,526 |
| 24-04-18 | 746 | -0.64% | 1,717,347 |
Delayed Quote Nyse, April 24, 2024 at 04:00 pm EDT
More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
2024-04-30
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
732.2
USD
Average target price
813.3
USD
Spread / Average Target
+11.08%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +25.61% | 672B | |
| +25.87% | 570B | |
| -5.24% | 360B | |
| +16.49% | 321B | |
| +8.28% | 300B | |
| +7.09% | 217B | |
| -9.12% | 204B | |
| +5.01% | 199B | |
| -8.75% | 149B | |
| -5.21% | 147B |
- Stock Market
- Equities
- LLY Stock
